510 related articles for article (PubMed ID: 10974034)
1. Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells.
Abrams JR; Kelley SL; Hayes E; Kikuchi T; Brown MJ; Kang S; Lebwohl MG; Guzzo CA; Jegasothy BV; Linsley PS; Krueger JG
J Exp Med; 2000 Sep; 192(5):681-94. PubMed ID: 10974034
[TBL] [Abstract][Full Text] [Related]
2. CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris.
Abrams JR; Lebwohl MG; Guzzo CA; Jegasothy BV; Goldfarb MT; Goffe BS; Menter A; Lowe NJ; Krueger G; Brown MJ; Weiner RS; Birkhofer MJ; Warner GL; Berry KK; Linsley PS; Krueger JG; Ochs HD; Kelley SL; Kang S
J Clin Invest; 1999 May; 103(9):1243-52. PubMed ID: 10225967
[TBL] [Abstract][Full Text] [Related]
3. Costimulation blockade promotes the apoptotic death of graft-infiltrating T cells and prolongs survival of hepatic allografts from FLT3L-treated donors.
Li W; Lu L; Wang Z; Wang L; Fung JJ; Thomson AW; Qian S
Transplantation; 2001 Oct; 72(8):1423-32. PubMed ID: 11685115
[TBL] [Abstract][Full Text] [Related]
4. Costimulation of superantigen-activated T lymphocytes by autologous dendritic cells is dependent on B7.
Nestle FO; Thompson C; Shimizu Y; Turka LA; Nickoloff BJ
Cell Immunol; 1994 Jun; 156(1):220-9. PubMed ID: 7515331
[TBL] [Abstract][Full Text] [Related]
5. CD69, HLA-DR and the IL-2R identify persistently activated T cells in psoriasis vulgaris lesional skin: blood and skin comparisons by flow cytometry.
Ferenczi K; Burack L; Pope M; Krueger JG; Austin LM
J Autoimmun; 2000 Feb; 14(1):63-78. PubMed ID: 10648117
[TBL] [Abstract][Full Text] [Related]
6. CD28 blockade alters cytokine mRNA profiles in cardiac transplantation.
Lin H; Wei RQ; Goodman RE; Bolling SF
Surgery; 1997 Aug; 122(2):129-37. PubMed ID: 9288115
[TBL] [Abstract][Full Text] [Related]
7. Characterization of human inducible costimulator ligand expression and function.
Aicher A; Hayden-Ledbetter M; Brady WA; Pezzutto A; Richter G; Magaletti D; Buckwalter S; Ledbetter JA; Clark EA
J Immunol; 2000 May; 164(9):4689-96. PubMed ID: 10779774
[TBL] [Abstract][Full Text] [Related]
8. [Regulation of T-cell activation by CD28 and CTLA-4].
Nagel T; Kalden JR; Manger B
Med Klin (Munich); 1998 Oct; 93(10):592-7. PubMed ID: 9849050
[TBL] [Abstract][Full Text] [Related]
9. Complementarity determining region 1 (CDR1)- and CDR3-analogous regions in CTLA-4 and CD28 determine the binding to B7-1.
Peach RJ; Bajorath J; Brady W; Leytze G; Greene J; Naemura J; Linsley PS
J Exp Med; 1994 Dec; 180(6):2049-58. PubMed ID: 7964482
[TBL] [Abstract][Full Text] [Related]
10. Blockade of CD28/B7-2 costimulation inhibits experimental obliterative bronchiolitis in rat tracheal allografts: suppression of helper T cell type1-dominated immune response.
Tikkanen JM; Lemström KB; Koskinen PK
Am J Respir Crit Care Med; 2002 Mar; 165(5):724-9. PubMed ID: 11874822
[TBL] [Abstract][Full Text] [Related]
11. Differential effect of CTLA4Ig on murine graft-versus-host disease (GVHD) development: CTLA4Ig prevents both acute and chronic GVHD development but reverses only chronic GVHD.
Via CS; Rus V; Nguyen P; Linsley P; Gause WC
J Immunol; 1996 Nov; 157(9):4258-67. PubMed ID: 8892665
[TBL] [Abstract][Full Text] [Related]
12. Chronic blockade of CD28-B7-mediated T-cell costimulation by CTLA4Ig reduces intimal thickening in MHC class I and II incompatible mouse heart allografts.
Glysing-Jensen T; Räisänen-Sokolowski A; Sayegh MH; Russell ME
Transplantation; 1997 Dec; 64(12):1641-5. PubMed ID: 9422395
[TBL] [Abstract][Full Text] [Related]
13. Blockade of multiple costimulatory receptors induces hyporesponsiveness: inhibition of CD2 plus CD28 pathways.
Woodward JE; Qin L; Chavin KD; Lin J; Tono T; Ding Y; Linsley PS; Bromberg JS; Baliga P
Transplantation; 1996 Oct; 62(7):1011-8. PubMed ID: 8878397
[TBL] [Abstract][Full Text] [Related]
14. CD28-B7 T cell costimulatory blockade by CTLA4Ig in the rat renal allograft model: inhibition of cell-mediated and humoral immune responses in vivo.
Akalin E; Chandraker A; Russell ME; Turka LA; Hancock WW; Sayegh MH
Transplantation; 1996 Dec; 62(12):1942-5. PubMed ID: 8990393
[TBL] [Abstract][Full Text] [Related]
15. T helper-independent activation of human CD8+ cells: the role of CD28 costimulation.
Van Gool SW; Zhang Y; Kasran A; de Boer M; Ceuppens JL
Scand J Immunol; 1996 Jul; 44(1):21-9. PubMed ID: 8693288
[TBL] [Abstract][Full Text] [Related]
16. CD28-B7-mediated T cell costimulation in chronic cardiac allograft rejection: differential role of B7-1 in initiation versus progression of graft arteriosclerosis.
Kim KS; Denton MD; Chandraker A; Knoflach A; Milord R; Waaga AM; Turka LA; Russell ME; Peach R; Sayegh MH
Am J Pathol; 2001 Mar; 158(3):977-86. PubMed ID: 11238045
[TBL] [Abstract][Full Text] [Related]
17. Analysis of the costimulatory requirements for generating human virus-specific in vitro T helper and effector responses.
Blazevic V; Trubey CM; Shearer GM
J Clin Immunol; 2001 Jul; 21(4):293-302. PubMed ID: 11506200
[TBL] [Abstract][Full Text] [Related]
18. CTLA4-Ig: a novel immunosuppressive agent.
Najafian N; Sayegh MH
Expert Opin Investig Drugs; 2000 Sep; 9(9):2147-57. PubMed ID: 11060799
[TBL] [Abstract][Full Text] [Related]
19. CTLA-4 (CD152) can inhibit T cell activation by two different mechanisms depending on its level of cell surface expression.
Carreno BM; Bennett F; Chau TA; Ling V; Luxenberg D; Jussif J; Baroja ML; Madrenas J
J Immunol; 2000 Aug; 165(3):1352-6. PubMed ID: 10903737
[TBL] [Abstract][Full Text] [Related]
20. The CD28-B7 costimulatory pathway and its role in autoimmune disease.
Daikh D; Wofsy D; Imboden JB
J Leukoc Biol; 1997 Aug; 62(2):156-62. PubMed ID: 9261329
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
